Details
Stereochemistry | RACEMIC |
Molecular Formula | C9H13NO3 |
Molecular Weight | 183.2044 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CNCC(O)C1=CC(O)=C(O)C=C1
InChI
InChIKey=UCTWMZQNUQWSLP-UHFFFAOYSA-N
InChI=1S/C9H13NO3/c1-10-5-9(13)6-2-3-7(11)8(12)4-6/h2-4,9-13H,5H2,1H3
Molecular Formula | C9H13NO3 |
Molecular Weight | 183.2044 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
Racepinephrine or racemic epinephrine is a mixture of levo and dextro isomers of epinephrine act as a nonselective agonist at adrenergic receptors. It is a bronchodilator used in the temporary relief of mild symptoms of intermittent asthma including wheezing, shortness of breath. Inhaled racepinephrine became available in September 2012 as a nonprescription treatment for bronchospasm based on a 1986 US Food and Drug Administration rule. Besides, racemic epinephrine relieves respiratory distress in hospitalized infants with bronchiolitis and is safe but does not abbreviate hospital stay. Morbidity associated with bronchiolitis as identified by parents persists for at least one week after hospital discharge in most infants.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2331074 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22220172 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | Unknown Approved UseFor temporary relief of mild symptoms of intermittent asthma: wheezing, tightness of chest, shortness of breath |
|||
Palliative | Unknown Approved UseUnknown |
Doses
Dose | Population | Adverse events |
---|---|---|
50 mg single, oral Overdose |
unknown, 2 years n = 1 Health Status: unknown Age Group: 2 years Sex: M Population Size: 1 Sources: |
Disc. AE: Hypertension, Tachycardia... AEs leading to discontinuation/dose reduction: Hypertension (5.4%) Sources: Tachycardia (5.4%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Hypertension | 5.4% Disc. AE |
50 mg single, oral Overdose |
unknown, 2 years n = 1 Health Status: unknown Age Group: 2 years Sex: M Population Size: 1 Sources: |
Tachycardia | 5.4% Disc. AE |
50 mg single, oral Overdose |
unknown, 2 years n = 1 Health Status: unknown Age Group: 2 years Sex: M Population Size: 1 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
A comparison of effects measured with isotonic and isometric recording: II. Concentration-effect curves for physiological antagonists. | 2001 Aug |
|
Characterization of [(3)H]idazoxan binding sites on human platelets. | 2002 Jun |
|
Long-term stability study of L-adrenaline injections: Kinetics of sulfonation and racemization pathways of drug degradation. | 2004 Apr |
|
Cardiovascular responses of Chinook salmon (Oncorhynchus tshawytscha) during rapid anaesthetic induction and recovery. | 2004 Feb |
|
Extravasation of blood-borne immunoglobulin G through blood-brain barrier during adrenaline-induced transient hypertension in the rat. | 2004 Jun |
|
MAPK-dependent regulation of IL-1- and beta-adrenoreceptor-induced inflammatory cytokine production from mast cells: implications for the stress response. | 2004 Sep 21 |
|
Opposite changes in imidazoline I2 receptors and alpha2-adrenoceptors density in rat frontal cortex after induced gliosis. | 2005 Nov 26 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/show/NCT00817466
Bronchiolitis: 0,1ml<5kg, 0,15ml 5-6,9kg, 0,20ml 7-9,9kg, 0,25ml >10kg of racemic adrenaline (racepinephrine) 20mg/ml diluted in 2ml NaCl. Maximum 12 inhalations/24 hours
Route of Administration:
Other
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 17:01:50 GMT 2023
by
admin
on
Sat Dec 16 17:01:50 GMT 2023
|
Record UNII |
GR0L9S3J0F
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Official Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C48149
Created by
admin on Sat Dec 16 17:01:51 GMT 2023 , Edited by admin on Sat Dec 16 17:01:51 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
66887
Created by
admin on Sat Dec 16 17:01:51 GMT 2023 , Edited by admin on Sat Dec 16 17:01:51 GMT 2023
|
PRIMARY | RxNorm | ||
|
DTXSID80858965
Created by
admin on Sat Dec 16 17:01:51 GMT 2023 , Edited by admin on Sat Dec 16 17:01:51 GMT 2023
|
PRIMARY | |||
|
4553
Created by
admin on Sat Dec 16 17:01:51 GMT 2023 , Edited by admin on Sat Dec 16 17:01:51 GMT 2023
|
PRIMARY | |||
|
8059-19-6
Created by
admin on Sat Dec 16 17:01:51 GMT 2023 , Edited by admin on Sat Dec 16 17:01:51 GMT 2023
|
SUPERSEDED | |||
|
CHEMBL1740
Created by
admin on Sat Dec 16 17:01:51 GMT 2023 , Edited by admin on Sat Dec 16 17:01:51 GMT 2023
|
PRIMARY | |||
|
100000085694
Created by
admin on Sat Dec 16 17:01:51 GMT 2023 , Edited by admin on Sat Dec 16 17:01:51 GMT 2023
|
PRIMARY | |||
|
GR0L9S3J0F
Created by
admin on Sat Dec 16 17:01:51 GMT 2023 , Edited by admin on Sat Dec 16 17:01:51 GMT 2023
|
PRIMARY | |||
|
SUB10238MIG
Created by
admin on Sat Dec 16 17:01:51 GMT 2023 , Edited by admin on Sat Dec 16 17:01:51 GMT 2023
|
PRIMARY | |||
|
4508
Created by
admin on Sat Dec 16 17:01:51 GMT 2023 , Edited by admin on Sat Dec 16 17:01:51 GMT 2023
|
PRIMARY | |||
|
206-347-6
Created by
admin on Sat Dec 16 17:01:51 GMT 2023 , Edited by admin on Sat Dec 16 17:01:51 GMT 2023
|
PRIMARY | |||
|
C76546
Created by
admin on Sat Dec 16 17:01:51 GMT 2023 , Edited by admin on Sat Dec 16 17:01:51 GMT 2023
|
PRIMARY | |||
|
DB11124
Created by
admin on Sat Dec 16 17:01:51 GMT 2023 , Edited by admin on Sat Dec 16 17:01:51 GMT 2023
|
PRIMARY | |||
|
33568
Created by
admin on Sat Dec 16 17:01:51 GMT 2023 , Edited by admin on Sat Dec 16 17:01:51 GMT 2023
|
PRIMARY | |||
|
329-65-7
Created by
admin on Sat Dec 16 17:01:51 GMT 2023 , Edited by admin on Sat Dec 16 17:01:51 GMT 2023
|
PRIMARY | |||
|
m4944
Created by
admin on Sat Dec 16 17:01:51 GMT 2023 , Edited by admin on Sat Dec 16 17:01:51 GMT 2023
|
PRIMARY | Merck Index | ||
|
6912-68-1
Created by
admin on Sat Dec 16 17:01:51 GMT 2023 , Edited by admin on Sat Dec 16 17:01:51 GMT 2023
|
SUPERSEDED | |||
|
8060-13-7
Created by
admin on Sat Dec 16 17:01:51 GMT 2023 , Edited by admin on Sat Dec 16 17:01:51 GMT 2023
|
SUPERSEDED | |||
|
838
Created by
admin on Sat Dec 16 17:01:51 GMT 2023 , Edited by admin on Sat Dec 16 17:01:51 GMT 2023
|
PRIMARY | |||
|
GR0L9S3J0F
Created by
admin on Sat Dec 16 17:01:51 GMT 2023 , Edited by admin on Sat Dec 16 17:01:51 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
ENANTIOMER -> RACEMATE | |||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
ENANTIOMER -> RACEMATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |